You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 DIAGNOSTICS LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Simultaneous kinetic analyses of neuronal connectivities

    SBC: CIENCIA INC            Topic: 101

    DESCRIPTION provided by applicant Aberrant neuronal connectivity is associated with a number of neuropathological and neuropsychiatric diseases disorders Inefficient developmental connectivity misdirected connectivity or disrupted and degenerated connectivity can account for losses of normal neuronal communication and subsequent losses of mental or physical health Altered expression of axon ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Topical application of heterologous protein-expressing Staphylococcus epidermidis for potential therapeutic treatment of skin diseases

    SBC: Azitra Inc.            Topic: NIAID

    PROJECT SUMMARY Current treatment options for a number of skin diseases generally aim for symptomatic relief and fail to address underlying pathophysiological changes leading to skin disease In the case of genetic mutations that cause loss of function mutations supplementation of the missing protein is a viable approach to treatment However delivery of functional protein to the target keratino ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Stabilization of Influenza Vaccine by Silica-Coating

    SBC: STONESTABLE, INC.            Topic: NIAID

    The goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under ambient environmental conditions Currently vaccines are either stabil ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Cognitive Change Battery: An Assessment for Serial Administration

    SBC: COGMETRIC LLC            Topic: NIA

    ABSTRACT Detecting change in neuropsychological functioning over time is critical for proper diagnosis and management of many neurological psychiatric and psychological conditions It is well documented that most commonly used cognitive assessments produce significant retest effects such as practice and regression to the mean effects Retest effects can cause substantial changes in test score ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial to the pathogenesis of P aeruginosa in vivo but has not yet been exploited for antimicrobial drug discovery There is a clear need for new treatments to combat P aeruginosa infections Antibiotic re ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government